Dysplastic (Atypical) Nevi

  • Mai P. Hoang
  • Martin C. MihmJr.


Dysplastic nevi or atypical lentiginous nevi are clinically atypical and have histologic architectural disorder and cytologic atypia. The significance of atypical nevi was emphasized by reports of atypical moles in family members with hereditary melanoma. The genetic change, mutations in the CDKN2A gene, results in a predisposition in certain patient in the development of malignant melanoma. Within members of familial melanomas, the presence of atypical nevi is associated with a 50 % risk of developing melanoma by age 50 years. Therefore, dysplastic nevi are significant in that they can be mimics of melanoma histologically, precursors to melanoma, and indicators of increased melanoma risk. In this chapter, the various features necessary to render the diagnosis of dysplastic nevus as well as the grading of these lesions are outlined.


Cytologic Atypia Melanocytic Nevus CDKN2A Gene Dysplastic Nevus Rete Ridge 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ahmed I, Piepkorn MW, Rabkin MS, Meyer LJ, Feldkamp M, Goldgar DE, et al. Histopathologic characteristics of dysplastic nevi. J Am Acad Dermatol. 1990;22(5Pt1):727–33.PubMedCrossRefGoogle Scholar
  2. Barnhill RL. Current status of the dysplastic melanocytic nevus. J Cutan Pathol. 1991;18(3):147–59.PubMedCrossRefGoogle Scholar
  3. Barnhill RL, Roush GC. Histopathologic spectrum of clinically atypical melanocytic nevi. II. Studies of nonfamilial melanoma. Arch Dermatol. 1990;126(10):1315–8.PubMedCrossRefGoogle Scholar
  4. Barnhill RL, Roush GC, Duray PH. Correlation of histologic architectural and cytoplasmic features with nuclear atypia in atypical (dysplastic) nevomelanocytic nevi. Hum Pathol. 1990;21(1):51–8.PubMedCrossRefGoogle Scholar
  5. Black WC, Hunt WC. Histologic correlations with the clinical diagnosis of dysplastic nevus. Am J Surg Pathol. 1990;14(1):44–52.PubMedCrossRefGoogle Scholar
  6. Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science. 1992;258(5085):1148–52.PubMedCrossRefGoogle Scholar
  7. Clark Jr WH, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesions. ‘The B-K mole syndrome’. Arch Dermatol. 1978;114(5):732–8.PubMedCrossRefGoogle Scholar
  8. Clemente C, Cochran AJ, Elder DE, Levene A, MacKie RM, Mihm MC, et al. Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol. 1991;22:313–9.PubMedCrossRefGoogle Scholar
  9. Crutcher WA, Sagebiel RW. Prevalence of dysplastic naevi in a community practice (letter). Lancet. 1984;1(8379):729.PubMedCrossRefGoogle Scholar
  10. Duncan LM, Berwick M, Bruijn JA, Byers R, Mihm MC, Barnhill RL. Histopathologic recognition and grading of dysplastic melanocytic nevi: an interobserver agreement study. J Invest Dermatol. 1993;100(3):318S–21.PubMedCrossRefGoogle Scholar
  11. Elder DE. The dysplastic nevus. Pathology. 1985;17(2):291–7.PubMedCrossRefGoogle Scholar
  12. Elder DE. Dysplastic nevi: an update. Histopathology. 2010;56:112–20.PubMedCrossRefGoogle Scholar
  13. Elder DE, Goldman LI, Goldman SC, Greene MH, Clark Jr WH. Dysplastic nevus syndrome. A phenotypic association of sporadic cutaneous melanoma. Cancer. 1980;46(8):1787–94.PubMedCrossRefGoogle Scholar
  14. Frichot III BC, Lynch HT, Guirgis HA, Harris RE, Lynch JF. New cutaneous phenotype in familial malignant melanoma. Lancet. 1977;1(8016):864–5.PubMedCrossRefGoogle Scholar
  15. Greene MH, Clark Jr WH, Tucker MA, Elder DE, Kraemer KH, Fraser MC, et al. Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature [letter]. Lancet. 1980;2(8202):1024.PubMedCrossRefGoogle Scholar
  16. Hastrup N, Clemmenson OJ, Spaun E, Sondergaard K. Dysplastic naevus: histopathologic criteria and their inter-observer reproducibility. Histopathology. 1994;24(6):503–9.PubMedCrossRefGoogle Scholar
  17. Knoell KA, Hendrix JD, Patterson JW, McHargue CA, Wilson BB, Greer KE. Nonpigmented dysplastic melanocytic nevi. Arch Dermatol. 1997;133(8):992–4.PubMedCrossRefGoogle Scholar
  18. Kumar R, Angelini S, Snellman E, Hemminki K. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol. 2004;122:342–8.PubMedCrossRefGoogle Scholar
  19. Lynch HT, Frichot III BC, Lynch JF. Familial atypical multiple mole-melanoma syndrome. J Med Genet. 1978;15(5):352–6.PubMedCentralPubMedCrossRefGoogle Scholar
  20. Nordlund JJ, Kirkwood J, Forget BM, Scheibner A, Albert DM, Lerner E, et al. Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res. 1985;45(4):1855–61.PubMedGoogle Scholar
  21. Norris W. Case of fungoid disease. EMSJ. 1820;16:562–5.Google Scholar
  22. Papp T, Schipper H, Kumar K, Schiffmann D, Zimmermann R. Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi. Melanoma Res. 2005;15:401–7.PubMedCrossRefGoogle Scholar
  23. Piepkorn M, Barnhill RL, Cannon-Albright LA, Elder DE, Goldgar DE, Lewis CM, et al. A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. J Am Acad Dermatol. 1994;30(5 Pt 1):707–14.PubMedCrossRefGoogle Scholar
  24. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19–20.PubMedCrossRefGoogle Scholar
  25. Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM, et al. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res. 2006;16(4):267–73.PubMedCrossRefGoogle Scholar
  26. Pozo L, Naase M, Cerio R, Blanes A, Diaz-Cano SJ. Critical analysis of histologic criteria for grading atypical (dysplastic) melanocytic nevi. Am J Clin Pathol. 2001;115(2):177–9.CrossRefGoogle Scholar
  27. Reimer RR, Clark Jr WH, Greene MH, Ainsworth AM, Fraumeni Jr JF. Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome. JAMA. 1978;239:746–74.CrossRefGoogle Scholar
  28. Rhodes AR, Mihm Jr MC, Weinstock MA. Dysplastic melanocytic nevi: a reproducible histologic definition emphasizing cellular morphology. Mod Pathol. 1989;2(4):206–19.Google Scholar
  29. Rigel DS, Rivers JK, Friedman RJ, Kopf AW. Risk gradient for malignant melanoma in individuals with dysplastic naevi. Lancet. 1988;1(8581):352–3.PubMedCrossRefGoogle Scholar
  30. Rigel DS, Rivers JK, Kopf AW, Friedman RJ, Vinokur AF, Heilman ER, et al. Dysplastic nevi. Markers for increased risk for melanoma. Cancer. 1989;63(2):386–9.PubMedCrossRefGoogle Scholar
  31. Rivers JK, Cockerell CJ, McBride A, Kopf AW. Quantification of histologic features of dysplastic nevi. Am J Dermatopathol. 1990;12(1):42–50.PubMedCrossRefGoogle Scholar
  32. Roth ME, Grant-Kels JM, Ackerman AB, Elder DE, Friedman RJ, Heilman ER, et al. The histopathology of dysplastic nevi. Am J Dermatopathol. 1991;13(1):38–51.PubMedCrossRefGoogle Scholar
  33. Roush GC, Barnhill RL, Duray PH, Titus LF, Ernstoff MS, Kirkwood JM. Diagnosis of dysplastic nevus in different populations. J Am Acad Dermatol. 1986;14(3):419–25.PubMedCrossRefGoogle Scholar
  34. Saldanha G, Purnell D, Fletcher A, Potter L, Gillies A, Pringle JH. High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer. 2004;111:705–10.PubMedCrossRefGoogle Scholar
  35. Shea CR, Vollmer RT, Prieto VG. Correlating architectural disorder and cytologic atypia in Clark (dysplastic) melanocytic nevi. Hum Pathol. 1999;30(5):500–5.PubMedCrossRefGoogle Scholar
  36. Slade J, Marghoob AA, Salopek TG, Rigel DS, Kopf AW, Bart RS. Atypical mole syndrome: risk factor for cutaneous malignant melanoma and implications for management. J Am Acad Dermatol. 1995;32(3):479–94.PubMedCrossRefGoogle Scholar
  37. Steijlen PM, Bergman W, Herman J, Schefer E, Van Vloten WV, Ruitter DJ. The efficacy of histopathological criteria required for diagnosing dysplastic naevi. Histopathology. 1988;12:289–300.PubMedCrossRefGoogle Scholar
  38. Tripp JM, Kopf AW, Marghoob AA, Bart RS. Management of dysplastic nevi: a survey of fellows of the American Academy of Dermatology. J Am Acad Dermatol. 2002;46(5):674–82.PubMedCrossRefGoogle Scholar
  39. Tucker MA, Fraser MC, Goldstein SC, Elder DE, Guerry 4th D, Organic SM. Risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol. 1993;100(3):350S–5.PubMedCrossRefGoogle Scholar
  40. Wachsmuth RC, Harland M, Bishop JA. The atypical-mole syndrome and predisposition to melanoma. N Engl J Med. 1998;339(5):348–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Harvard Medical SchoolBostonUSA
  2. 2.Department of PathologyMassachusetts General HospitalBostonUSA
  3. 3.Department of DermatologyBrigham and Women’s HospitalBostonUSA
  4. 4.Melanoma ProgramDana Farber Brigham and Women’s Cancer CenterBostonUSA

Personalised recommendations